文献速递儿科与产科急症

足月计划分娩预防子痫前期(PREVENT-PE):一项开放标签随机对照试验

Scheduled birth at term for the prevention of pre-eclampsia (PREVENT-PE): an open-label randomised controlled trial.
PubMed 文献 · Lancet · 2025-12-04
一句话结论36周妊娠子痫前期风险筛查联合风险分层计划早期足月分娩使子痫前期发生率从5.6%降至3.9%(校正RR 0.70),未增加急诊剖宫产或新生儿监护病房入住。

PREVENT-PE是一项在英国两家产科医院进行的开放标签、适应性随机对照试验,纳入16岁及以上、单胎、活胎无重大畸形、无子痫前期且能提供知情同意的孕妇。在35+0至36+6周常规胎儿超声时随机1:1分为干预组(子痫前期风险评估,风险≥1/50者接受风险分层计划早期足月分娩)或对照组(足月常规护理)。最终分析8094例,干预组4037例中子痫前期158例(3.9%),对照组4057例中226例(5.6%),校正RR 0.70(95% CI 0.58-0.86)。严重不良事件两组无差异(干预组5/4031 vs 对照组10/4048,Fisher精确检验p=0.30)。作者认为基于子痫前期风险分层的计划早期足月分娩降低了子痫前期发生率,且未增加急诊剖宫产或新生儿监护病房入住。

要点

  • 在35+0至36+6周对单胎孕妇进行子痫前期风险评估,风险≥1/50者接受风险分层计划早期足月分娩,子痫前期发生率3.9% vs 5.6%(校正RR 0.70,95% CI 0.58-0.86)。
  • 干预组严重不良事件5/4031(0.1%) vs 对照组10/4048(0.2%),Fisher精确检验p=0.30,两组无差异。
  • 作者结论认为计划早期足月分娩未增加急诊剖宫产或新生儿监护病房入住。
  • 最终分析8094例中2098例(25.9%)自报非白人种族,5996例(74.1%)自报白人种族。

适用人群与场景

  • 纳入:年龄≥16岁、单胎妊娠、活胎无重大畸形、能提供知情同意、无子痫前期且未参与冲突试验的孕妇,在英国两家产科医院于35+0至36+6周常规胎儿超声时入组。
  • 排除:子痫前期患者及参与冲突试验者。

诊断标准与关键阈值

  • 子痫前期风险评估:风险≥1/50的孕妇接受风险分层计划早期足月分娩。
  • 主要结局子痫前期诊断采用国际妊娠高血压研究学会(International Society for the Study of Hypertension in Pregnancy)标准。

处置流程与药物剂量

  • 干预组:在35+0至36+6周进行子痫前期风险评估,对风险≥1/50者提供风险分层计划早期足月分娩。
  • 对照组:足月常规护理。

研究设计与关键结果

  • 研究类型:开放标签、适应性(样本量计划)、随机对照试验,在英国两家产科医院进行;2023年5月9日至2024年6月7日筛查11 280例,10 803例(95.8%)符合条件,8136例(75.3%)随机分组,6例(0.1%)撤回知情同意、36例(0.4%)错误随机,最终分析8094例(99.5%):干预组4037例(49.9%),对照组4057例(50.1%)。
  • 主要终点:干预组子痫前期158/4037(3.9%) vs 对照组226/4057(5.6%),校正RR 0.70(95% CI 0.58-0.86),意向性治疗分析含插补。
  • 严重不良事件:干预组5/4031(0.1%) vs 对照组10/4048(0.2%),Fisher精确检验p=0.30。
  • 作者结论:基于子痫前期风险分层的计划早期足月分娩降低了子痫前期发生率,未增加急诊剖宫产或新生儿监护病房入住。

证据类型、等级与局限

  • 证据类型:开放标签随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,基于子痫前期风险分层的计划早期足月分娩可降低子痫前期发生率,且未增加急诊剖宫产或新生儿监护病房入住。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In high-risk pregnancies, there is no reliable intervention to reduce term pre-eclampsia. We aimed to investigate the effect of screening for pre-eclampsia risk at 36 weeks' gestation and offering risk-stratified, planned, early-term birth.

METHODS: PREVENT-PE was an open-label, adaptive (planned, for sample size), randomised controlled trial, done at two maternity hospitals in the UK. We included women (aged ≥16 years) with a singleton pregnancy, live fetus without major anomalies, and ability to provide informed consent, without pre-eclampsia or participation in conflicting trials. Consenting women were randomly assigned (by a central computerised service, 1:1, in random permuted blocks of variable size, stratified by site) to the intervention group (pre-eclampsia risk assessment and, for women with a pre-eclampsia risk ≥1 in 50, risk-stratified planned early-term birth) or control group (usual care at term). The primary outcome was birth with pre-eclampsia (International Society for the Study of Hypertension in Pregnancy criteria). This trial is registered with ISRCTN, ISRCTN41632964.

FINDINGS: Of 11 280 women presenting for routine fetal ultrasound at 35+0 to 36+6 weeks' gestation between May 9, 2023, and June 7, 2024, 10 803 (95·8%) were eligible. Of 8136 women (75·3%) randomly assigned, six (0·1%) withdrew consent and 36 (0·4%) were randomly assigned in error, leaving 8094 (99·5%) in the final analyses: 4037 (49·9%) women in the intervention group and 4057 (50·1%) in the control group. 2098 (25·9%) of 8094 women self-reported non-White ethnicity and 5996 (74·1%) self-reported White ethnicity. Pre-eclampsia occurred in 158 (3·9%) of 4037 births in the intervention group and in 226 (5·6%) of 4057 in the control group (adjusted risk ratio 0·70 [95% CI 0·58-0·86]; intention-to-treat analysis with imputation). Serious adverse events did not differ between the intervention group (five [0·1%] of 4031) and control group (ten [0·2%] 4048; Fisher's exact test p=0·30).

INTERPRETATION: Planned early-term birth based on risk stratification for pre-eclampsia reduced the incidence of pre-eclampsia, without increasing emergency caesarean section or neonatal care unit admission.

FUNDING: Fetal Medicine Foundation.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Goadsby J, Syngelaki A, Magee LA, et al. Scheduled birth at term for the prevention of pre-eclampsia (PREVENT-PE): an open-label randomised controlled trial. Lancet. 2025. PMID: 41354041. doi:10.1016/S0140-6736(25)01207-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。